Effects of Ang 1-7 and Endothelial Microvesicles on Ang II-induced Dysfunction and Apoptosis in Cerebral Endothelial Cells by Xiao, Xiang
Wright State University 
CORE Scholar 
Browse all Theses and Dissertations Theses and Dissertations 
2013 
Effects of Ang 1-7 and Endothelial Microvesicles on Ang II-
induced Dysfunction and Apoptosis in Cerebral Endothelial Cells 
Xiang Xiao 
Wright State University 
Follow this and additional works at: https://corescholar.libraries.wright.edu/etd_all 
 Part of the Pharmacology, Toxicology and Environmental Health Commons 
Repository Citation 
Xiao, Xiang, "Effects of Ang 1-7 and Endothelial Microvesicles on Ang II-induced Dysfunction and 
Apoptosis in Cerebral Endothelial Cells" (2013). Browse all Theses and Dissertations. 759. 
https://corescholar.libraries.wright.edu/etd_all/759 
This Thesis is brought to you for free and open access by the Theses and Dissertations at CORE Scholar. It has 
been accepted for inclusion in Browse all Theses and Dissertations by an authorized administrator of CORE 
Scholar. For more information, please contact library-corescholar@wright.edu. 
 
EFFECTS OF ANG 1-7 AND ENDOTHELIAL MICROVESICLES ON ANG 
II-INDUCED DYSFUNCTION AND APOPTOSIS IN CEREBRAL 
ENDOTHELIAL CELLS 
  
 
 
 
 
 
 
 
 
A thesis submitted in partial fulfillment of the 
 requirements for the degree of  
Master of Science 
 
 
 
By 
 
 
 
Xiang Xiao 
B.S., University of South China, 2010 
 
 
 
 
 
 
 
 
 
 
 
 
2013  
Wright State University 
 
 
 
 
 
 
 
 
WRIGHT STATE UNIVERSITY 
 
GRADUATE SCHOOL 
 
                                                 August 26, 2013 
I HEREBY RECOMMEND THAT THE THESIS PREPARED UNDER MY 
SUPERVISION BY Xiang Xiao ENTITLED Effects of Ang 1-7 and Endothelial 
Microvesicles on Ang II-induced Dysfunction and Apoptosis in Cerebral 
Endothelial Cells BE ACCEPTED IN PARTIAL FULFILLMENT OF THE 
REQUIREMENTS FOR THE DEGREE OF Master of Science. 
 
 
 
                                                                    
                                          Yanfang Chen, M.D., Ph.D. 
                                            Thesis Director 
                                  
 
                                                                      
                                           Norma C. Adragna, Ph.D.,  
Interim Chair, Department of 
Pharmacology and Toxicology 
 
Committee on 
Final Examination 
                              
     Yanfang Chen, M.D., Ph.D. 
                              
     David. R. Cool, Ph.D. 
                              
     Richard Simman, M.D. 
                              
     R. William Ayres, Ph.D. 
Interim Dean, Graduate School 
 
 
 
 
 
ABSTRACT 
 
 
Xiang Xiao, M.S. Department of Pharmacology and Toxicology, Wright State 
University, 2013. Effects of Ang 1-7 and Cellular Vesicles on Ang II-Induced 
Dysfunction and Apoptosis in Cerebral Endothelial Cells. 
 
 
 
Angiotensin II (Ang II) induces endothelial dysfunction and is implicated in the 
pathogenesis of vascular diseases. Angiotensin 1-7 (Ang 1-7) has been 
reported to counteract many deleterious effects of Ang II. Endothelial 
microvesicles (EMVs) are small membrane vesicles released from endothelial 
cells (ECs) undergoing stress and apoptosis. But their functions are largely 
unknown. In this study, we investigated the effects of Ang 1-7 and EMVs on 
apoptosis and dysfunction of human brain microvascular endothelial cells 
(HbmECs). Reactive oxygen species (ROS) and nitric oxide (NO) production, 
and Nox2, p-Akt/Akt, p-eNOS/eNOS expression were analyzed. We found that 
Ang II dose-dependently induced HbmEC apoptosis and that both Ang 1-7 and 
EMVs can counteract the effects of Ang II. Their protective effects were 
associated with ROS/NO production which were linked to Nox2, and Akt 
/eNOS pathways. Our data suggests that both Ang 1-7 and EMVs protect 
endothelial dysfunction and apoptosis induced by Ang II in HbmECs. 
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I. INTRODUCTION 
 
Part 1: Angiotensin Axis and Endothelial Dysfunction 
Renin angiotensin system (RAS) 
The renin angiotensin system (RAS) is a hormonal cascade in regulation of 
cardiovascular, renal, and adrenal function that governs body fluid and 
electrolyte homeostasis, as well as arterial pressure. It has been extensively 
studied since the first description of renin by Tigerstedt and Bergmann in 1898. 
The classical RAS consists of a circulating endocrine system in which the 
principal effector hormone is Angiotensin (Ang) II. Ang II is a biologically active 
octapeptide that is produced by the action of renin on angiotensinogen to form 
Ang I and then subsequently convert to Ang II by Ang-converting enzyme 
(ACE). The actions of Ang II are mediated via the Ang type 1 receptor (AT1 
receptor). However, the current view of RAS system is characterized by an 
increased complexity, as evidenced by the discoveries of new functional 
components and actions of the RAS, including local tissue RAS, a (pro)renin 
receptor, ACE2, Ang 1-7, Mas receptor, the function of the Ang type 2 receptor 
(AT2 receptor). Studies have demonstrated the importance of a tissue RAS in 
the brain, heart, blood vessels, adrenal glands, kidney and etc [1-5].  
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Although some of the components that necessary for the biosynthesis of the 
active peptide product (Ang II) may be taken up from the circulation into the 
tissue, the local tissue RAS defines the de novo tissue generation of Ang II and 
its interaction with Ang II receptor on the same (autocrine) or adjacent 
(paracrine) cells [6]. 
 
The RAS cascade (Fig 1) is activated in response to reduced perfusion which 
result in renin secretion and release into circulation [6]. Renin cleaves the 
angiotensinogen to form the inactive decapeptide Ang I. The catabolism of Ang 
I serves as a point of divergence in the system, leading not only to the 
production of the bioactive octapeptide Ang II by ACE [7], but also to the 
formation of the active peptide Ang 1-7 by prolylendopeptidase and neprilysin 
[8]. ACE2 is a recently identified homologue of ACE, which can catalyze Ang I 
to Ang 1-9 [9], with subsequent conversion to Ang 1-7 by ACE or 
neutral-endopeptidase [10]. ACE2 is also highly effective in the conversion of 
Ang II to Ang 1–7, which has approximately 400-fold more affinity to Ang II 
than to Ang I [11]. Ang II can further be degraded by aminopeptidase (AMP) 
and dipeptidyl-aminopeptidase to produce Ang III and Ang IV, respectively [12]. 
Of note, Ang IV can be produced from Ang III by the activity of AMP. Ang 1-7 
can be metabolized by ACE to form the inactive degradation products Ang 1-5 
[13]. 
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Figure 1. RAS cascade. AGT: angiotensinogen; Ang: angiotensin; ACE: 
angiotensin-converting enzyme; AT1 R: Ang II type 1 receptor; AT2 R: Ang II 
type 2 receptor; Mas R: Ang 1-7 receptor; AMP: aminopeptidase; D-Amp: 
dipeptidyl-aminopeptidase; PCP: prolyl-carboxypeptidase; PEP: 
prolylendopeptidase; NEP: neutral-endopeptidase; (P)RR: (pro)renin receptor. 
 
The physiological and pathological roles of RAS 
The RAS is a complex regulatory system which plays an important role in 
mediating both physiological and pathological functions. The main 
physiological stimuli for RAS activation are low salt intake, blood volume and 
BP. In turn, Ang II acts to help raise blood volume and BP, thereby prevent 
hypovolemia and hypotension. 
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The main physiological roles of RAS are: 1) to prevent life-threatening 
shrinkage of intravascular volume (rapid actions of Ang II). 2) to help achieve 
sodium balance without large alterations in BP (slower actions of Ang II). 3) to 
increase the efficiency of cardiovascular dynamics by promoting the growth of 
the heart and vessels, and sensitizing blood vessels to vasoconstrictor agents 
(slowest actions of Ang II). The functions of the RAS from the general point of 
view is being homeostatic. However it will be harmful if carried to excess. 
Indeed, increased activity of the RAS, especially in combination with other 
cardiovascular risks factors, may lead to a cascade of deleterious effects such 
as hypertension, cardiovascular hypertrophy, oxidative stress with endothelial 
dysfunction, atherosclerosis and tissue inflammation [14]. In recent years, the 
pathophysiological implications of the system have been the main focus of 
attention, inhibitors of the RAS such as ACE inhibitors and Ang II receptor 
blockers have become important clinical tools in the treatment of 
cardiovascular and renal diseases such as hypertension, heart failure, and 
diabetic nephropathy [15].  
 
Two counteracting axes in RAS 
There are two counteracting axes that exist in RAS: ACE/Ang II/AT1 receptor 
axis and ACE2/Ang 1-7/Mas receptor axis. The ACE/Ang II/AT1 receptor is a 
classical RAS axis. Ang II produced from Ang I by ACE is a well-known 
bioactive substance in the regulation of blood pressure and is involved in the 
exaggeration of vascular disease [16]. The major receptor subtypes for Ang II 
are the AT1 and AT2 receptors. Both the AT1 and the AT2 receptors belong to  
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the superfamily of G protein-coupled receptors that contains seven 
transmembrane regions. They share about 34% homology and have distinct 
signal transduction pathways. The distribution of AT1 receptor covers most 
organs [17], whereas AT2 receptor expression is observed in only a few 
organs after birth and is up-regulated in pathological states [18;19]. AT1 
receptor stimulation mediates the classical major actions of Ang II and is 
known to cause vasoconstriction, inflammation, fibrosis, cellular 
growth/migration and fluid retention (Table 1) [20]. These findings are also 
closely related to the development of RAS inhibitors, such as ACE inhibitors 
(ACEi) and AT1 receptor blockers (ARBs), promoting the basic and clinical 
research in the RAS. Accordingly, They are widely used as antihypertensive, 
cardiovascular and renoprotective drugs with well-documented effectiveness. 
Nevertheless, important limitations have been reported related to the use of 
these drugs. For instance, besides their potential side effects, the responses to 
ACEi treatment are influenced by gender and ethnic diversity and ARBs have 
limited efficacy in treatment of end-organ damage [21]. AT2 receptor 
stimulation appears to antagonize the effects mediated by AT1 receptor  
stimulation. Therefore, AT2 receptor stimulation could contribute to the effects  
of ARBs [18;19;22].  
 
The ACE2/Ang 1–7/Mas axis has been highlighted as the counteracting 
partner of the ACE/Ang II/AT1 receptor axis. Ang 1-7 is now recognized as a 
biologically active component of RAS since it exerts a vast array of actions, 
many of them opposite to those attributed to Ang II. It was initially regarded as  
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an inactive component of the RAS for many years. However, in recent years, 
two pivotal discoveries clearly established Ang 1-7 as an active RAS mediator. 
First, the existence and characterization of ACE2, which was established later 
as the main Ang 1-7 forming enzyme [23;24]. Second, the G-protein coupled 
Mas receptor was discovered as a functional receptor for its endogenous 
ligand Ang 1-7 [25]. In mammals, Mas receptor is expressed predominantly in 
brain and testis with moderate levels of expression in heart and kidney [26;27]. 
Thus, Ang 1-7 is now considered a biologically active member of the RAS, 
which binds to Mas receptor to induce many beneficial actions, such as 
vasodilation, inhibition of cell growth, anti-inflammation, anti-thrombosis and 
anti-fibrosis [28;29]. 
 
Table 1. Two counteracting axes in RAS. Ang I: angiotensin I; Ang II: 
angiotensin II; Ang 1-7: angiotensin 1-7; ACE: angiotensin converting enzyme; 
ACE2: angiotensin converting enzyme 2; AT1: angiotensin II type 1 receptor;  
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RAS Axis ACE/Ang II/AT1 R ACE2/Ang 1-7/Mas R
Substrate Ang I Ang II
Enzyme ACE ACE2
Receptor AT1 Mas
Effects Vasoconstriction;
inflammation; 
thrombosis; fibrosis; 
sodium reabsorption 
cellular migration
Vasodilatation; 
anti-inflammation; 
anti-thrombosis; anti-fibrosis;
anti-hypertrophy; 
antiproliferation
Metabolites Ang 1-7 (by ACE2) 
Ang III (by AMP)
Ang IV (by D-AMP)
Ang 1-5 (by ACE) 
 
Mas: angiotensin 1-7 receptor; AMP: aminopeptidase; D-Amp: 
dipeptidyl-aminopeptidase; Ang1-5: angiotensin 1-5; Ang III: angiotensin III 
(2-8). 
 
Ang II/Ang 1-7 balance regulates endothelial function  
Endothelium is the active inner monolayer of the blood vessels, forming an 
interface between circulating blood and the vessel wall. It represents the 
largest organ in the body and plays a critical role in vascular homeostasis. 
Endothelial cells regulate vascular tone by releasing various contracting and 
relaxing factors including nitric oxide (NO), arachnoid acid metabolites, 
reactive oxygen species (ROS), and vasoactive peptides. In addition, the 
endothelium actively regulates vascular permeability, inflammatory activity, cell 
proliferation, as well as the balance between coagulation and fibrinolysis. 
Endothelial dysfunction is referred as impaired endothelium-dependent 
vasodilation (reduction of the bioavailability of vasodilators and increase of 
endothelium-derived contracting factors). In addition to that, endothelial 
dysfunction also comprises a specific state, which is characterized by 
increased vascular permeability, cell proliferation, and a proinflammatory and 
prothrombotic phenotype (including leucocyte-endothelial interactions and 
increased adhesion and aggregation of platelets) [30;31].  Oxidative stress 
can induce vascular endothelial dysfunction. ROS are generated at sites of 
inflammation and injury. It can function as signaling molecules that participate 
in the regulation of fundamental cell activities such as cell growth and cell 
adaptation responses at low concentrations; whereas, ROS can cause cellular  
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injury and death at higher concentrations [32]. Exogenous ROS can be 
produced from pollutants, tobacco, smoke, drugs, xenobiotics, or radiation. 
What's more, ROS can be produced intracellularly through multiple 
mechanisms, the major sources being mitochondria, peroxisomes, 
endoplasmic reticulum, and the nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase complex in the cell membranes.  
Ang II has significant pro-inflammatory actions in the vascular wall, inducing 
the production of ROS, cytokines, adhesion molecules and chemokines [33]. 
The endothelial dysfunction caused by Ang II is mainly through the reduction of 
NO bioavailability and imbalance between the ROS and antioxidant capacity. 
In endothelial cells (Figure 2), NADPH oxidase catalytic subunit gp91phox 
(Nox2) is activated by Ang II when it binds to the AT1 receptor [34]; The 
NADPH oxidase (Nox) regulatory subunit p47phox is phosphorylated and 
translocated to p22phox. Increased p47phox-p22phox complex formation 
initiated Nox activation and subsequently ROS over-production [35]. Enhanced 
production of ROS (mainly O2-) are known to induce programmed cell death in 
the vascular ECs [36]. The pro-apoptotic effect of endogenous ROS induced 
by Ang II in ECs seems to involve the disturbance of mitochondrial membrane 
permeability, which is a prerequisite for cytochrome c release. The cytochrome 
c is regulated by the Bcl-2 protein family [37]. The Bcl-2 protein family can 
either promote (e.g., Bax) or inhibit apoptosis (e.g., Bcl-2, Bcl-XL). An 
imbalance between anti-apoptotic and pro-apoptotic members of Bcl-2 protein 
family will increase the mitochondrial membrane permeability, and then trigger 
the release of cytochrome c from the space between the inner and outer  
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mitochondrial membrane into the cytoplasm [36]. In the cytoplasm, the 
complex formation of cytochrome c and apoptotic peptidase activating factor 1 
(Apaf1) stimulates caspase-9 release, which results in the activation of 
caspase-3, which eventually leads to EC apoptosis. 
Through the detailed mechanism of Ang 1-7 counteracts the actions of Ang II 
remains unclear, accumulating evidences suggest that Ang 1-7 may oppose 
the endothelial dysfunction and apoptosis induced by Ang II either through 
directly inhibiting the activity of Nox or through stimulating NO production and 
subsequently inhibition of apoptosis executioner proteases (caspases) (Figure 
2) [38;39]. 
 
 
Figure 2. Ang II/Ang 1-7 balance in regulating endothelial cell function: Nox 
and Akt/eNOS signaling pathways. Ang II: angiotensin II; Ang 1-7: angiotensin 
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1-7; AT1 R: angiotensin II type 1 receptor; Mas R: Mas receptor; Nox: 
NAD(P)H oxidase; PI3K: phosphoinositide 3-kinases; p-Akt: protein Kinase B 
phosphorylation; eNOS: endothelial nitric oxide synthase. ROS: reactive 
oxygen species; NO: nitric oxide. 
 
PI3K/Akt/eNOS signaling pathways in endothelial cells 
NO plays a critical role in endothelial function by maintaining vasodilator tone, 
inhibiting platelet aggregation and adhesion [40]. Many risk factors implicated 
in cardiovascular diseases seem to be associated with impairment in the NO 
system [40;41]. Phosphoinositide 3-kinases (PI3K) and its downstream 
serine/threonine kinase Akt (also known as Protein Kinase B) play a central 
role in promoting the survival of a wide range of cell types, including ECs [42].  
PI3K constitutes a multifunctional family of enzymes activated by receptor 
tyrosine kinases, G protein coupled receptor and other stimuli. Upon receptor 
activation, PI3K subunit is recruited to the plasma membrane and binds to 
inositol lipids. These lipids serve as docking sites for proteins that harbor 
pleckstrin-homology domains, including Akt and its upstream activator 
phosphoinositide-dependent kinases 1 (PDK1). Once in the membrane, Akt is 
phosphorylated by PDK1, leading to the activation of Akt. Akt activation 
mediates the phosphorylation of endothelial NO synthase (eNOS), and thereby 
stimulates eNOS activity and increases NO release. Previous studies have 
found that Ang II had a biphasic effect on Akt phosphorylation [43;44]. It is 
suggested that low concentration Ang II causes a dose-dependent increase in 
Akt phosphorylation, while high concentration of Ang II lead to a decrease of  
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Akt phosphorylation in ECs [43;44]. Recent studies have suggested that Ang 
1-7 regulates EC function through functionally active Mas receptor, which 
stimulates eNOS activity and NO production through Akt-dependent pathways 
[45;46]. 
 
Part 2: Extracellular Vesicles and Endothelial Dysfunction 
Extracellular vesicles  
The extracellular space of multicellular organisms contains solutions of 
metabolites, ions, proteins and polysaccharides. However, it is clear that this 
extracellular environment also contains a large number of mobile 
membrane-limited vesicles for which the term of extracellular vesicles is 
suggested [47]. Extracellular vesicles are shed in response to cell activation, 
dysfunction, injury, or apoptosis. Major types of extracellular vesicles are 
exosomes, microvesicles (MVs) and apoptotic bodies (Figure 3). There is an 
increasing interest in the field on MVs and exosomes, whose release may 
represent a universal and evolutionarily conserved process. 
 
Key features of MVs and exosomes 
The key features (table 2) of exosomes include: 1) Exosomes are vesicles 
surrounded by a phospholipid bilayer (approximately 50–100 nm in diameter), 
their size range roughly overlaps that of the viruses [47]. 2) Exosomes are an 
end-product of the endocytic recycling pathway. First, endocytic vesicles form 
at the plasma membrane and fuse to form early endosomes. They become 
late endosomes where intraluminal vesicles (ILVs) bud off into the lumen.  
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These multivesicular bodies (MVBs) then directly fuse with the plasma 
membrane and release exosomes into the extracellular space. 3) Exosomes 
have been predominantly characterized in the case of immune cells (dendritic 
cells, T cell, B cells, macrophages) and tumors. 4) They feature 
phosphatidylserine (PS) on the outer membrane leaflet and exosomal markers 
such as CD63, CD81 and CD9 [48;49]. 5) Isolation methods include a slow 
centrifuge at 1500g for 15 minutes followed by 100 nm gravity-driven filtration. 
Exosomes are final pellet at 120,000 x g for 70 minutes [47]. For purer 
preparations, some researchers use sucrose gradient ultracentrifugation. 6) 
Transmission electron microscopy has been typically used to characterize 
exosomes due to their small size. Western blot and mass spectroscopy have 
been used to identify the proteomic profiles of exosomes. Bead-coupled flow 
cytometry can also be used to detect exosomes [47;50]. 
 
The key features (table 2) of MVs include: 1) MVs are structures surrounded 
by a phospholipid bilayer (approximately 100–1000 nm in diameter). Their size 
range overlaps that of bacteria and insoluble immune complexes [51]. 2) They 
are formed by regulated release by budding/blebbing of the plasma membrane. 
3) They have been predominantly characterized as products of platelets, red 
blood cells and ECs. 4) They feature PS on the outer membrane leaflet [52], 
tissue factor (TF) and cell specific markers. however, some observations also 
suggest the existence of MVs without PS externalization [52]. 5) Routine 
isolation methods include a slow centrifuge at 1500g for 15 minutes and 
followed by centrifuge at 18,000g for 30 min or 100,000g for 60 min [53]. 
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6) Flow cytometry is the commonest method for detecting MVs, transmission 
electron microscopy (TEM) and nanoparticle tracking analysis (NTA) were also 
used to detecting MVs [54;55]. 
 
Table 2. Key features of exosomes and MVs. MVBs: multivesicular bodies; TF: 
tissue factor. 
 
Potential use of endothelial-derived MVs and exosomes as biomarkers 
and their functional significance  
Both MVs and exosomes are released when cells undergo stress, activation or 
apoptosis. They can carry the characteristics of their parent cells, which enable 
them to serve as potential biomarkers for various diseases [47;56;57]. Of note, 
they also have been shown to mediate cell communications through the ability 
of transferring membrane proteins, phospholipids and RNAs from their parent 
cells to distant cells [58]. Recent novel pharmacological approaches have 
started to reveal the functions of MVs and exosomes. 
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Exosomes MVs
Size Range 30–100 nm in diameter 0.1 -1 µm in diameter
Biogenesis Exocytosis of MVBs 
Budding from plasma 
membrane
Markers
CD63, CD81, CD9, and 
Tsg101
Annexin V binding, TF 
and cell-specific markers 
 
Endothelial MVs (EMVs) result from endothelial plasma membrane blebbing 
and carry endothelial proteins such as vascular endothelial cadherin 
(VE-cadherin or CD144), E-selectin (CD62E), platelet endothelial cell 
adhesion molecule-1 (CD31) [59], intercellular cell adhesion molecule 
(ICAM)-1 (CD54), endoglin (CD105) , S-endo (CD146) or αv integrin (CD51) 
[60]. Among these, only CD62E and CD144 are the exclusive markers for 
EMVs. Like other MVs, EMVs also can transfer functional proteins and nuclear 
materials such as DNA, mRNA, and miRNA to target cells [58]. Although EMVs 
represent a sparse population of circulating MVs, their changes in plasma level 
might predict important clinical information [49]. The level of circulating EMVs 
are inversely correlated with the amplitude of flow-mediated dilatation in 
patients presenting endothelial dysfunction, independently of age and 
pressure [61]. 
 
The functional significance of EMVs has been proposed in recent years. Abid 
Hussein et al. first documented that EMV release could protect EC from 
apoptosis by diminishing caspase-3 level in cultured ECs [62]. EMVs 
contribute to the sorting of pro-apoptotic factors and the prevention of cell 
detachment and apoptosis. Moreover, EMVs carrying endothelial protein C 
receptor and activated protein C could also promote cell survival by inducting 
cytoprotective and anti-inflammatory effects [63]. One recent publication has 
described that the EMVs could protect ECs against apoptosis induced by 
camptothecin and that inhibition of p38MAPK activity is involved in 
EMV-mediated anti-apoptotic effect [64]. In most cases, the role of EMV  
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carried nuclear materials remains to be determined. A pioneering study by 
Deregibus et al. showed that endothelial progenitor cell derived MVs 
(EPC-MVs) were able to trigger an angiogenic program to ECs through 
shuttling mRNAs associated with the PI3K/AKT/eNOS signaling pathway [65]. 
Recently, Cantaluppi et al. suggested that EPC-MVs carrying miR-126 and 
miR-296 for inducing the activation of PI3K/Akt/eNOS signaling pathway in 
islet endothelium that may sustain revascularization and β-cell function [66].  
Endothelial exosomes are produced in MVBs during endocytosis and are 
well-known for antigen presentation [47]. Unlike MVs, they express specific 
exosomal markers such as CD63, Alix, tetraspanins and tumor susceptibility 
gene 101 (TSG101) [67]. Endothelial exosomes can serve as biomarkers 
since they contain functional proteins, mRNAs and miRNAs [68]. A recent 
study suggests that endothelial miR-214 containing exosomes repress the 
expression of ataxia telangiectasia in recipient ECs, thereby prevent 
senescence [59]. This emerging field is still relatively young considering the 
vast wealth of information, 
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II. HYPOTHESISES AND AIMS 
 
Part 1 
Hypothesis:  
It is hypothesized that Ang 1-7 protects hbmECs from Ang II-induced HbmEC 
dysfunction and apoptosis through down-regulation of Nox2 and activation of 
PI3K/Akt/eNOS signaling pathway.  
Specific Aims: 
Aim 1: To develop optimal concentration of Ang II for inducing HbmEC 
apoptosis. 
Aim 2: To evaluate the effects of Ang II/Ang 1-7 on HbmEC apoptosis, tube 
formation ability, ROS and NO production. 
Aim 3: To analyze the expression of Nox2, p-Akt/Akt and p-eNOS/eNOS.  
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Part 2 
Hypothesis:  
It is hypothesized that EMVs could serve as novel therapeutic resource for 
protecting HbmEC from dysfunction induced by Ang II. 
Specific Aims: 
Aim 1: To develop optimal procedures for EMV isolation and characterization.  
Aim 2: To analyze the effects of EMVs on HbmEC tube formation ability, ROS 
and NO production. 
Aim 3: To analyze the effects of EMVs on HbmEC expression of p-Akt/Akt and 
p-eNOS/eNOS. 
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III. EXPERIMENTAL DESIGNS 
 
Part 1 
Aim 1: 
HbmECs were cultured with Ang II treatment at different concentration (0, 10-9, 
10-8, 10-7, 10-6 M) for 24 hours. Then, the cells were collected and labeled with 
Annexin V/PI for apoptosis assay using flow cytometry. Passages 4-13th of 
HbmECs were used for the study. 
Aim 2: 
HbmECs were pre-treated with different concentrations of Ang 1-7 (0, 10-9, 10-8, 
10-7, 10-6 M) for 1 hour and  followed by Ang II (10-7 M) treatment for 24 hours. 
Then, the cells were collected and labeled with Annexin V/PI for apoptosis 
assay using flow cytometry. 
After the Ang 1-7 effective concentration (10-7 M) was identified, HbmECs were 
divided into seven treatment groups: vehicle; Ang II (10-7 M); Ang 1-7 (10-7 M);  
Ang II + Ang 1-7, Ang II + losartan (10-6 M); Ang II + Ang 1-7 + A779 (10-7 M) or 
+LY294002 (20 µM). Cells were collected for various assays: tube formation, 
cell apoptosis, ROS and NO production. Passages 4-13th of HbmECs were 
used for the study. 
Aim 3: 
HbmECs were treated in the same conditions as Aim 2. Then, the proteins 
were extracted from treated cells and used for analyzing Nox2, p-Akt/Akt and  
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e-NOS/eNOS expression by western blot. Passages 4-13th of HbmECs were 
used for the study. 
 
Figure 3: Experiment design for part 1. HbmECs: human brain microvascular 
endothelial cells; Ang II: angiotensin II; Ang 1-7: Angiotensin 1-7; FC: flow 
cytometry; ROS: reactive oxygen species; NO: nitric oxide; DHE:  
dihydroethidium; DAM-FM: 4-amino-5-methylamino- 2’,7’-difluorofluorescein; 
WB: western blot. 
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Figure 4: Detailed HbmEC tube formation assay demonstration. 
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Part 2 
Aim 1: 
HbmECs were staved under no-serum medium for 24 hours. HbmEC culture 
medium was collected and centrifuged at 1500g for 15 min. Supernatant was 
collected and subjected to 100 nm filter under gravity-driven force. EMVs were 
retrieved from the up-membrane of that filter using sterile PBS and followed by 
ultracentrifuged at 100,000g for 1 hour. EMV surface markers (Annexin V and 
CD144) were determined by flow cytometry. The morphology was examined by 
TEM. The size distribution and concentration were determined by NTA. 
Aim 2: 
HbmECs were divided into three treatment groups: Vehicle, Ang II (10-7 M), 
Ang II + EMVs (10 µg/ml). Cells were collected for various assays: tube 
formation, cell apoptosis, ROS and NO production. Passages 4-13th of 
HbmECs were used for the study. 
Aim 3: 
HbmECs (passages 4-13th) were treated in the same conditions as Aim 2. 
Then, the proteins were extracted from treated cells and used for analyzing 
p-Akt/Akt and e-NOS/eNOS expression by western blot. 
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Figure 5: Experiment design for part 2 (EMV isolation & characterization). 
HbmECs: human brain microvascular endothelial cells; EMVs: endothelial cell 
microvesicles; FC: flow cytometry; TEM: transmission electron microscopy; 
NTA: Nanosight tracking analysis. 
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Figure 6: Experiment design for part 2 (EMV function assay). HbmECs: human 
brain microvascular endothelial cells; Ang II: angiotensin II; EMVs: endothelial 
cell  microvesicles; FC: flow cytometry; ROS: reactive oxygen species; NO: 
nitric oxide; DHE:  dihydroethidium; DAM-FM: 4-amino-5-methylamino- 
2’,7’-difluorofluorescein; WB: western blot. 
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IV. MATERIALS AND METHODS 
 
HbmEC Culture  
Human brain microvascular endothelial cells (HbmECs) were purchased from 
Cell Systems Corp. (Kirkland, WA, USA). HbmECs were cultured in CSC 
complete medium (Cell Systems) containing 10% serum, supplemented with 2% 
human recombinant growth factors (CSC CultureBoost-R, Cell Systems) and 
0.2% Bac-OffR antibiotic solution (Cell Systems) under standard cell culture 
conditions (37°C, 5% CO2). Cells of 4 to 13 passage were used in this study. 
During cell growth, medium was changed every 2 or 3 days after washed 1 
time with phosphate buffer saline (PBS) and replaced with fresh CSC complete 
medium. Upon confluence, cells were detached using a passage reagent 
group (Cell Systems) following manufacturer’s protocol, resuspended in CSC 
complete medium and replated in tissue culture well. Precoated with 
attachment factor (Cell Systems) is a necessary step before seeding cells. 
Subsequently, cells were maintained in CSC complete medium prior to the 
assays. 
 
HbmEC characterization was performed by double staining of cultured cells 
with 1,1’-dioctadecy1-3,3,3’,3’-tetramethylindocarbocyanine-labeled 
acetylated low-density lipoprotein (DiI-acLDL) and Lectin from Bandeiraea  
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simplicifolia (BS-lectin). Briefly, cells were incubated with DiI-acLDL (10µg/ml; 
Biomedical Technologies, Stoughton, USA) at 37°C for 1 hour. Cells were then 
fixed with 0.5% paraformaldehyde (PFA) for 10 minutes, and incubated with 
FITC-conjugated Bs-lectin (20µg/ml; Sigma-Aldrich, St. Louis, USA) at 4°C for 
4 hours. The cells were also stained with nuclear staining dye 
4',6-diamidino-2-phenylindole (DAPI; 1 μg/ml; Wako Pure Chemical Industries 
Ltd, Osaka, Japan) for 20 min at room temperature (RT). After the staining, 
cells were examined with an inverted fluorescent microscope (EVOS, 
Washington, USA). Double-stained cells for both Bs-lectin and DiI-acLDL were 
considered as HbmECs. 
 
Isolation of EMVs 
Confluent cells were starved by subjecting to CSC serum free medium for 24 
hours. After starvation, the supernatant of HbmEC culture was collected and 
centrifuged at 1500g for 15 minutes to remove cell and cell debris. The 
supernatant was then subjected to 100 nm syringe filter (CellTreat, 
Gaithersburg, MD, USA) under gravity-driven force. EMVs (particle size 
around 100 nm to 1um) on the upper membrane of filter were retrieved by 
using syringe pump containing PBS and centrifuged at 100,000g for 60 
minutes at 4 °C.  
 
Characterization of EMVs 
Isolated EMVs were characterized by flow cytometry based on the surface  
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markers of EMVs. CD144 was used to identify events as EMVs. For analysis of 
EMVs, freshly isolated MVs were resuspended in PBS and incubated for 30 
min at RT in the dark with 5 μl of PE-conjugated anti-mouse CD144 (1:25, 
eBioscience). Isotype matched PE-labeled nonspecific antibody 
(Sigma-Aldrich) was served as negative control. After incubation, size 
calibration of EMVs was performed using 1 and 2 µm flow cytometry beads 
(Molecular Probes, Invitrogen, Eugene, OR). Labeled EMVs were subjected to 
flow cytometric analysis. The flow cytometer (BD Accuri C6, San Jose, USA) 
was set to acquire 100,000 events/sample. The EMVs were defined as 
particles with size smaller than 1 µm, and CD144+ events, in the gate of MVs.  
Transmission electron microscopy (TEM) was used to determine the size and 
morphology of EMVs. The EMVs pellets were fixed with 500 µl 2% 
glutaraldehyde in 1x PBS for 1 hour at 4°C and centrifuged again at 30,000 × g 
for 30 min. The samples were washed with 1x PBS for 3 times (1 minute each), 
fixed with 1% osmium tetroxide (OsO4) in 1x PBS for 2 hours at 4°C and 
washed another 3 times (1 minute each), then dehydrated with a graded 
ethanol series (50%, 75%, 95%, 100%) for 5 minutes each. Subsequently, the 
samples were treated with 100% propylene oxide 2 times (5 minute each), and 
then treated with 1:2 ratio of spurrs resin and propylene oxide, followed by a 
2:1 ratio of spurrs resin and propylene oxide for 2 hours. Finally, the samples 
were embedded in beam capsules with spurrs resin according to the 
manufacture’s instruction, baked at 60°C in a hot air oven overnight. Ultrathin 
sections (60 nm) were prepared with MT7000 and mounted on 300-mesh 
copper grids, stained with 2% uranyl acetate for 5 minutes, rinsed with double 
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distilled water for 5 times, and allowed to dry. The specimens were then 
stained with lead citrate for 10 min (REYNOLDS, 1963), rinsed with double 
distilled water another 5 times and allowed to air dry. Finally, all specimens 
were examined with an EM 208 (Philips) transmission electron microscope at 
an accelerating voltage of 70 KV. EMVs were visible as small (100 - 1000 nm), 
rounded objects with clear, intact membranes.  
NanoSight LM10 instrument (NanoSight, Amesbury, UK) was used to measure 
the size and concentration of EMVs. When samples contained higher numbers 
of particles (over 2 × 108/ml), they were diluted using PBS before analysis, and 
the relative concentration was then calculated according to the dilution factor. 
A video of 30 to 60s duration was taken with a frame rate of 30 frames/s, and 
particle movement was analyzed by NTA software (version 2.2, NanoSight). 
The NTA software is optimized to first identify and then track each particle on a 
frame-by-frame basis, and its Brownian movement is tracked and measured 
from frame to frame. In NTA, the paths of MVs acting as point scatters, 
undergoing Brownian motion. The velocity of particle movement is used to 
calculate particle size distribution by applying the two-dimensional 
Stokes–Einstein equation. Since MVs have a low refractive index, their range 
of sizes that can be analyzed by NTA using low refractive index, and the 
smallest detectable size using the NTA system is approximately 50 nm. NTA 
postacquisition settings were optimized and kept constant between samples, 
and each video was then analyzed to give the mean, mode, and median 
vesicle size together with an estimate of the concentration. 
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Incorporation of EMVs In Target Cells 
To study the capacity of EMVs to incorporate into HbmECs, EMVs were 
labeled with PKH-26 dye (1 x 10-6 M, Sigma-Aldrich) for 30 min at 37 °C. After 
that, EMVs were washed twice with sterile PBS and centrifuged at 100,000g 
for 60 minutes. After that, EMVs were resuspended and washed in sterile PBS. 
HbmEC were incubated with PKH26-labeled EMVs for different time frames 
(0.5, 3, 6, 12, 24 hours). After 3 washing steps with PBS, HbmECs were fixed 
in 2% paraformaldehyde (PFA) for 20 minutes. Nuclei were stained with DAPI 
(1 μg/ml, Wako Pure Chemical Industries Ltd) for 10 minutes. Incorporation of 
EMVs into HbmEC was observed by fluorescence light microscopy. 
 
Apoptosis Assay 
For cell apoptosis assay, we used the FITC Annexin V Apoptosis Detection Kit 
(BD Biosciences, CA, USA). Briefly, the cells after different treatments were 
collected and washed twice with cold PBS, and then resuspended in 100 µl 1X 
Annexin-binding buffer. After that, 5 µl FITC-conjugated Annexin V and 5 µl 
propidium iodide (PI) were added into cell suspension. The samples were then 
gently vortexed and incubated at RT ( ~25°C) for 15 min in the dark. The 
apoptotic cells were recognized as Annexin V+ / PI-  cells. The percentage of 
apoptotic cells was analyzed by flow cytometer (BD Accuri C6, San Jose, 
USA). 
 
Tube Formation Assay 
HbmEC tube formation assay was performed by using a tube formation assay  
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kit (BD Biosciences). Briefly, BD Matrigel matrix solution was thawed on ice 
overnight, and 250μl of chilled BD Matrigel matrix (10 mg/ml) was place in 
each well of a 24-well culture plate at 37°C for 1 hour to allow the matrix 
solution to solidify. HbmECs were replated (2 X 104 cells/well) on top of the 
solidified matrix solution and incubated at 37°C for 24 hours. After that, tubes 
were labeled by adding 300 μl/well of 8 μg/ml BD calcein AM in Hanks 
Balanced Salt Solution (HBSS) and incubated for 30 minutes at 37°C. After 
that, labeling solution was removed and plate was washed twice with HBSS. 
HbmEC tube formation was evaluated with an inverted fluorescence 
microscope (EVOS, Washington, USA). Tubes were quantified by counting 
sprouting capillary-like structures exhibiting lengths four times their width. Five 
independent fields were assessed for each well, and the average number of 
tubes per field was determined. 
 
Measurement of ROS Generation 
Intracellular ROS production in HbmECs was determined by dihydroethidium 
(DHE) (Invitrogen Molecular Probes, Eugene, OR, USA) staining and followed 
by flow cytometric analysis. DHE is a cell-permeable compound that upon 
entering the cells, it interacts with O2- to form oxyethidium, which in turn 
interacts with nucleic acids to emit a bright red color detectable qualitatively by 
fluorescent microscope. Briefly, HbmECs were incubated with DHE (2 μmol/L) 
in dark for 30 min and rinse off excess DHE with PBS twice. Red fluorescence 
was visualized by an fluorescence microscopy. After that, HbmECs were 
trypsinized and collected by centrifuge at 300g, 8 minutes, 4°C. Fluorescence 
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intensity was analyzed by a flow cytometer (BD Accuri C6, San Jose, USA). 
For each sample, 10,000 events were collected. 
 
Determination of Nitric Oxide Production 
The membrane-permeable indicator diaminofluorescein diacetate (DAF-FM 
DA)    (Life technology, Grand Island, NY, USA) was used to assess NO 
production released by HbmECs. This FAF-FM DA is converted by intracellular 
esterases to form the DAF-FM, which reacts with NO to form green fluorescent 
product. Briefly, cells were loaded with 10 μM DAF-FM DA in CSC serum free 
medium (37°C for 60 minutes, in dark), washed twice with PBS and incubated 
with CSC serum free medium (37°C for 30min, in dark) for de-esterification of 
the intracellular diacetates. DAF-FM DA fluorescence was visualized by 
inverted fluorescence microscopy and measured using a spectrofluorometer. 
 
Western Blot Analysis 
The levels of Nox2, Akt/p-Akt and eNOS/p-eNOS in HbmECs were determined 
by western blot analysis. Cells were harvested after different treatments and 
resuspended in Lysis-M reagent containing complete protease inhibitor tablets 
(1 tablet/10 ml lysis reagent, Roche Diagnostics, Germany). Pipette thoroughly, 
followed by vortex-mixing. keep it on ice and sonicated for 3 times. Centrifuge 
the sample at 13,000g for 5 minutes at RT, transfer the supernatant (protein) to 
a new tube. Proteins were subjected to sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE, 12% Bis-Tris Novex mini-gel, Invitrogen) and 
transferred onto polyvinylidene difluoride (PVDF) membrane (Invitrogen). The 
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PVDF membrane was blocked by incubating with 5% non-fat dry milk and 
Tris-buffered saline with Tween 20 (TBS-T; 1X TBS with 0.1% Tween-20) for 1 
hour and then incubated with antibodies against Nox2 (1:1000; Abcam), p-Akt 
(1:1000; Cell Signaling Technology), p-eNOS (1:1000; Cell Signaling 
Technology), Akt (1:1000; Cell Signaling Technology), eNOS (1:1000; Cell 
Signaling Technology) at 4°C overnight. β-actin (1:4000, Sigma, MO) was used 
to normalize protein loading. After being washed with TBS-T for 3 times (5 
minutes each), membranes were incubated with horseradish peroxidase (HRP) 
conjugated IgG (1:40000, Jackson Lab) for 1 hour at RT. Blots were then 
developed with enhanced chemiluminescence developing solutions and 
quantified. 
 
Statistical Analysis 
Results are expressed as means ± SEM of at least four experiments. 
Differences between 2 groups were performed by the Student t-test. Multiple 
comparisons were analyzed by 1- or 2-way ANOVA. For all tests, a P<0.05 
was considered significant. All comparisons were performed using the 
statistical package SPSS 16.0 for Window. 
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V. RESULTS 
 
1. Characterization of HbmECs 
The cultured HbmECs showed a typical, cobblestone morphology of ECs 
(Figure 7A). When cultured under standard conditions (37°C, 5% CO2). 
HbmECs were defined as cells binding with Bs-Lectin (Figure 7B)  and 
up-taking Di-acLDL (Figure 6C).  
 
Figure 7. Characterization of HbmECs by Dil-acLDL and Bs-lectin double 
staining. A: HbmECs without staining, cells showed a typical, cobblestone 
morphology of ECs; B: Bs-Lectin staining  (Green); C: Di-acLDL up-taking  
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(Red); D: DAPI nuclear staining (Blue); E: Di-acLDL and Bs-Lectin positive 
cells (Yellow); scale bar: 200 µm. 
 
2. The dose-response effect of Ang II on HbmEC apoptosis  
To determine whether Ang II is involved in programmed cell death, HbmECs 
were treated with various concentrations (0, 10-9, 10-8, 10-7, 10-6 M) of Ang II 
for 24 hours. Flow cytometric assay of Annexin V/PI staining showed that Ang 
II dose-dependently induced apoptosis in HbmECs (Figure 8). HbmECs 
treatment with 10-8 M, 10-7 M and 10-6 M of Ang II increased the apoptotic 
rate by about 2.2-, 2.6- and 2.5-fold when compared to control (basal medium) 
(P<0.01; n=4). There was no significant difference between the apoptotic rate 
in cells cultured with 10-9 M Ang II and control, whereas the apoptotic rate is 
significant higher in cells treated with Ang II at the concentration of 10-7 M than 
10-9 M (P<0.05, n=4). Thus, the concentration of Ang II was established by 
using 10-7 M for further experiments. 
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Figure 8. The dose-dependent effect of Ang II on HbmEC apoptosis. HbmECs 
were treated with Ang II at different concentration (0, 10-9, 10-8, 10-7, 10-6 M) for 
24 hours, and then cells were collected and subjected to cell apoptosis 
analysis. n = 4. #P<0.05 vs vehicle; * P<0.05 vs 10-9 M Ang II. 
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3. Ang 1-7 improves the tube formation ability compromised by Ang II in 
HbmECs 
As shown in Figure 8, the ability of HbmEC tube formation was attenuated in 
Ang II-treated group by about 36% when compared with control (P<0.01). 
Pretreatment with Ang 1-7 enhanced tube formation ability of HbmECs by 42% 
(P<0.05) when compared with Ang II alone. Moreover, losartan and A779 
blocked Ang II-induced impairment and Ang 1-7-induced enhancement of tube 
formation in HbmECs, respectively (P<0.01). 
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Figure 9. Ang 1-7 improves the tube formation ability of HbmECs compromised 
by Ang II. A: Representative tube formation figures. A1: vehicle; A2: Ang II; 
A3:Ang 1-7; A4: Ang II + Ang 1-7; A5: Ang II + losartan;  A6: Ang II + Ang 1-7 
+ A779; scale bar: 200 µm. B: Summarized data. Data are the mean ± SEM, n 
= 4. ## P<0.01 vs Control, ++P<0.01 vs Ang II, &&P<0.01 vs Ang II + Ang 1-7. 
 
4. The dose-response effect of Ang 1-7 on cell apoptosis induced by Ang 
II in HbmECs 
To quantify the anti-apoptotic effects of Ang 1–7 on Ang II-induced apoptosis 
on  bmECs, flow cytometry analysis after Annexin V/PI staining was 
conducted (Figure 10A). The percentage of Annexin V-positive stained cells 
was enhanced by exposure to Ang II (10-7 M) alone compared to control cells 
(P<0.01). Pretreatment with Ang 1-7 markedly reduced the apoptotic rate 
caused by Ang II, and the degree of suppression was significantly increased at 
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higher concentrations (10-7 and 10-6 M) of Ang 1-7. Thus, the concentration of 
Ang 1-7 was established by using 10-7 M for further experiments. 
We used receptor/pathway blockers to further determine the mechanism in 
apoptotic effect of Ang II and anti-apoptotic effect of Ang 1-7, respectively 
(Figure 10B). Measurement of annexin V/PI staining by flow cytometry also 
showed that Ang II mainly induced early apoptosis (Annexin V+/PI- events). 
10-7 M Ang II significantly increased the rate of apoptosis to 23.8 ± 7% 
(P<0.01), 10-7 M Ang 1–7 alone had no effect on the rate of apoptosis of 
HbmECs compared with the control group (P>0.05). Pre-incubation with Ang 
1-7 attenuated Ang II-induced apoptosis (P<0.01). Ang II-induced apoptosis 
was inhibited by AT1 receptor antagonist losartan (10-7 M) (P<0.01). The Mas 
receptor antagonist A-779 (10-6 M) almost completely abolished the protective 
effects of Ang 1–7 on HbmEC apoptosis (P< 0.01). The PI3K inhibitor 
LY294002 (20 μM) partially abolished the protective effects of Ang1–7 on 
HbmEC apoptosis (P<0.01). 
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Figure 10. Ang 1-7 decreases apoptosis induced by Ang II in HbmECs. A: 
HbmECs were pre-treated with different concentrations of Ang 1-7 (0, 10-9, 
10-8, 10-7, 10-6 M) for 1 hour and followed by Ang II (10-7 M) treatment for 24 
hours. B: Data summary for HbmEC apoptosis  under different treatment 
groups. Data are the mean ± SEM, n = 4. ##P<0.01 vs Control, ++P<0.01 vs 
Ang II, &P<0.05, &&P<0.01 vs Ang II + Ang 1-7. 
 
5. Ang 1-7 decreases the production of ROS induced by Ang II in 
HbmECs 
DHE fluorescent dye and flow cytometric analysis were used to investigate the 
effect of Ang 1-7 on Ang II-induced ROS production. Results showed that DHE 
fluorescence (red) was increased by about 2.7-fold after 24 hours stimulation 
of Ang II (Figure 11A). Pretreatment with Ang 1-7 reduced the intensity of DHE 
fluorescence by about 37% when compared with Ang II, reflecting a reduction 
in ROS generation. Flow cytometric analysis (Figure 11B) showed that the 
peak of the signal moved to the right, corresponding to increased DHE 
fluorescence after incubation with Ang II. This increase in fluorescence 
intensity was markedly reduced, as evidenced by a leftward shift after 
treatment with Ang 1-7 in addition to Ang II, which reflected a reduction in ROS 
generation. The effects that induced by Ang II and Ang 1-7 were neutralized by 
their receptor antagonist losartan and A779, respectively. The protective effect 
of Ang 1-7 is partially blocked by the PI3K inhibitor (LY294002). 
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Figure 11. Ang 1-7 decreases Ang II-induced ROS production. A: 
Representative DHE staining images observed under microscope. A1: vehicle; 
A2: Ang II; A3: Ang 1-7; A4: Ang II + Ang 1-7; A5: Ang II + losartan;  A6: Ang II 
+ Ang 1-7 + A779; A7: Ang II + Ang 1-7 + LY294002; scale bar: 400 µm. B: 
Representative flow cytometric figures. B1: analysis control; B2: vehicle; B3: 
Ang II; B4: Ang 1-7; B5: Ang II + Ang 1-7; B6: Ang II + losartan; B7: Ang II + 
Ang 1-7 + A779; B8: Ang II + Ang 1-7 + LY294002. C: Summarized data. Data 
are the mean ± SEM, n = 4. ## P<0.01 vs Control, ++P<0.01 vs Ang II, 
&P<0.05, && P<0.01 vs Ang II + Ang 1-7.  
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6. Ang 1-7 increases the production of NO compromised by Ang II in 
HbmECs  
The NO production was lower (vs control; P<0.01; Figure 12) in the Ang 
II-treated HbmECs. Ang 1-7 treatment increased the NO production in 
HbmECs by about 1.8-fold when compared to control. Pre-treatment of Ang 
1-7 and losartan induced 1.72- and 1.62-fold of NO production in Ang II-treated 
group (P<0.01). In addition, A779 blocked those effects induced by Ang 1-7 
(P<0.01), and LY294002 partially  blocked the NO production induced by Ang 
1-7 treatment (P<0.01). 
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Figure 12. Ang 1-7 increases NO production of HbmECs compromised by Ang 
II . A: Representative DAM-FM staining figures. A1: vehicle; A2: Ang II; A3:Ang 
1-7; A4: Ang II + Ang 1-7; A5: Ang II + losartan;  A6: Ang II+ Ang 1-7 + A779; 
A7: Ang II + Ang 1-7+ LY294002; scale bar: 200 µm. B: Summarized data. 
Data are the mean ± SEM, n = 4. # P<0.05, ## P<0.01 vs Control, ++P<0.01 
vs Ang II, &&P<0.01 vs Ang II + Ang 1-7. 
 
7. Ang 1-7 counteracts Ang II on Nox2, p-Akt/Akt and p-eNOS/eNOS 
expression in HbmECs 
Ang II has been shown to increase Nox2 expression (P<0.01; Figure 13B), 
treatment with Ang 1-7 decreased Nox2 expression when compared with Ang 
II treatment (P<0.01; Figure 13B). Ang 1-7 has been shown to increase eNOS 
activity in an EC culture model, and to also induce NO production in human 
studies. However, the mechanism through which Ang 1-7 improves NO 
production in ECs has not been well defined. We hypothesized that Ang 1-7  
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could active the phosphorylation of Akt (p-Akt) and eNOS (p-eNOS), and 
ultimately increase NO production. Treatment with Ang II decreased the 
expression of p-Akt and p-eNOS (P<0.05 or 0.01; Figure 13C and D). Whereas, 
treatment with Ang 1-7 increased the expression of p-Akt and p-eNOS (P<0.05 
or 0.01; Figure 13C and D), Co-treatment of Ang 1-7 with Ang II increased 
p-Akt and p-eNOS expression in HbmEC. In addition, losartan (AT1 receptor 
antagonist) was able to block those effects of Ang II-induced on HbmECs，
A779 (Mas receptor antagonist) and LY294002 (PI3K inhibitor) were able to 
block those effects of Ang 1-7-induced on HbmECs. Our results also showed 
that addition of Ang II, Ang 1-7 or both have no changes in Akt or eNOS protein 
levels. The Ang II impairment of p-Akt and p-eNOS are not equivalent, with the 
reduction of p-Akt being greater. This suggests that another serine kinase may 
also be important in the phosphorylation of eNOS. 
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Figure 13: Ang 1-7 counteracting the effects of Ang II on Nox2, p-Akt/Akt and 
p-eNOS/eNOS expression in HbmECs. A: Representative western blot bands 
for Nox2, p-Akt/Akt and p-eNOS/eNOS. B: Summarized data for Nox2. C: 
Summarized data for p-Akt/Akt. D: Summarized data for p-eNOS/eNOS. Data 
are the mean ± SEM, n = 4. #P<0.05 vs control; +P<0.05, ++P<0.05 vs Ang II; 
&&P<0.01 vs Ang II + Ang 1-7. 
 
8. EMV characterization  
Flow cytometric analysis of EMVs was performed to determine the size and 
phenotype of EMV. Isolated EMVs were analyzed by using anti-CD144. The 
EMVs were defined as CD144 + (Figure 14 A3) MVs, at gate R1 with size 
small than 1.0 µm (Figure 14A1). Isotype antibody was used as negative 
control (Figure 14A2).  
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Transmission electron microscopy (TEM) showed that EMV had a spheroid 
morphology with size ≥ 100 nm (Figure 14B), and they were heterogenous in 
size. Nanoparticle  tracking analysis (NTA) was used to analyze the size and 
concentration of EMVs. The NTA gave a vesicle size distribution from 40 to 
653 nm with two peaks around 152 and 214 nm. ~ 80% of vesicles were larger 
than 100nm and the vesicle count was 3.54 x 1010 per ml (Figure14 C1). The 
screenshot of the same vesicles analyzed on the NanoSight LM10 showing a 
heterogenous size population of vesicles (Figure14 C2). 
 
 
Figure 14. Characterization of EMVs. Representative flow cytometric analysis 
of endothelial EMVs (A). A1: the position of 1- (blue circle) and 2-µm (yellow 
square) calibration beads and the R1 gate for MVs. A2: PE-conjugated isotype  
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control. A3: PE-conjugated CD144. EMVs were defined as CD144 + events in 
the gate of MVs. B: Isolated EMVs were observed by TEM; scale bar: 100 nm. 
C: Measurement of EMV by NTA (C). C1 and C2: Size curve (white line) and 
screen shot of video from NanoSight LM10 showing optimal light scatter from 
EMVs that were retrieved from the up-membrane of 100 nm filter.                    
 
9. EMVs uptaken by target cells after co-incubation  
Previous report indicated the possibility that protein and/or nucleic acids 
(mRNAs, miRNA) are packaged into MVs and exosomes and can be taken up 
by cells, acting as biomolecules. To elucidate whether EMVs can be uptaken 
by target cell, we incubated HbmECs with PKH26-labeled EMVs and analyzed 
after different time points. Immunofluorescence staining revealed that EMVs 
were detectable in the cytoplasm of target cells after 0.5 hour treatment, and 
that uptake in target cell was time dependent. To confirm that EMVs were 
incorporated into the cytoplasm of cells, DAPI nuclear staining was also 
applied. Fluorescence images showed that EMVs were internalized by 
HbmECs (Figure 15A). 
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Figure 15. EMVs are incorporated by HbmECs in a time-dependent manner. 
EMVs are incorporated by HbmECs in a time-dependent manner. 
Representative figures for HbmECs incubated with PKH26-labeled EMVs for 
24 hours (A). A1: DAPI staining (Blue). A2: PKH26-labeled EMVs (red). A3: 
Merged image for DAPI/PKH26-labeled EMVs; scale bar: 200 µm. B: 
Summarized data. Data are the mean ± SEM, n = 3.  
 
10. EMVs improve tube formation ability of HbmECs compromised by 
Ang II 
The ability of HbmEC tube formation was attenuated in Ang II-treated group by 
about 36% when compared with control (P<0.01; Figure 16B). Pretreatment 
with EMVs enhanced tube formation ability of HbmECs by 43% (P<0.01; 
Figure 16B) when compared with treatment with Ang II alone. 
 
 
49 
5
20
P
K
H
2
6 
la
b
el
ed
 E
M
V
s 
(p
er
 c
el
ls
) 15
10
1
B
 
 
 
 
Figure 16. EMVs improve tube formation ability of HbmEC compromised by 
Ang II. A: Representative tube formation pictures. A1: Vehicle; A2: 10-7 M Ang 
II; A3: 10-7 M Ang II + 10µg/ml EMVs; scale bar: 200 µm. B: Summarized data. 
Data are the mean ± SEM, n = 4. ##P < 0.01 vs control; ++P<0.01 vs 10-7 M 
Ang II.  
 
11. EMVs reduce ROS production of HbmECs induced by Ang II  
DHE fluorescent dye and flow cytometric analysis were used to investigate the 
effect of Ang 1-7 on Ang II-induced ROS production. Results showed that DHE 
fluorescence (red) was increased by about 2.7-fold after 24 hours stimulation  
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of Ang II (Figure 17). Pretreatment with Ang 1-7 reduced the intensity of DHE 
fluorescence by about 37% (P<0.01) when compared with Ang II, reflecting a 
reduction in ROS generation. The effects that induced by Ang II and Ang 1-7 
were neutralized by their receptor antagonist losartan and A779, respectively. 
The protective effect of Ang 1-7 also was partially blocked by the PI3K inhibitor 
(LY294002). Flow cytometric analysis showed that the peak of the signal 
moved to the right, corresponding to increased DHE fluorescence, after 
incubation with Ang II. This increase in fluorescence intensity was markedly 
reduced, as evidenced by a leftward shift after treatment with Ang 1-7 in 
addition to Ang II, which reflected a reduction in ROS generation.  
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Figure 17. EMVs decrease Ang II-induced ROS production. A: Representative 
DHE staining figures. A1: vehicle; A2: Ang II; A3: Ang II + EMVs; scale bar: 400 
µm. B: Representative flow cytometric figures. B1: analysis control; B2: vehicle; 
B3: Ang II; B4: Ang II + EMVs. C: Summarized data. Data are the mean ± SEM, 
n = 4. ## P<0.01 vs Control, ++P<0.01 vs Ang II. 
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12. EMVs increase the production of NO compromised by Ang II in 
HbmECs 
The NO production was lower (vs control; P<0.01; Figure 18) in the Ang 
II-treated HbmECs. Pre-treatment of EMVs and endothelial exosomes induced 
1.9- and 1.79-fold of NO production in Ang II-treated group, respectively. 
(P<0.01). 
 
 
Figure 18. EMVs increase NO production of HbmECs compromised by Ang II.    
A: Representative DAM-FM staining figures. A1: vehicle; A2: Ang II; A3:Ang II 
+ EMVs; scale bar: 400 µm. B: Summarized data. Data are the mean ± SEM, n 
= 4. ## P<0.01 vs Control, ++P<0.01 vs Ang II. 
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13. EMVs up-regulate the expression of p-Akt/Akt and p-eNOS/eNOS 
inhibited by Ang II in HbmECs 
As we found that EMV could inhibit endothelial dysfunction and apoptosis 
induced by Ang II, we hypothesized that EMVs might protect HbmEC 
dysfunction and apoptosis by activating the Akt/eNOS activity. The western 
blot analysis on p-Akt/Akt and p-eNOS/eNOS expression showed that Ang 
II-induced down-regulation of Akt and eNOS were activated after EMV 
treatment (Figure 19A). Treatment with Ang II decreased the expression of 
p-Akt and p-eNOS (P<0.05). Whereas, pre-treatment with EMVs increased the 
expression of p-Akt and p-eNOS expression in HbmECs, in the absence of 
changes in Akt and eNOS protein levels (P<0.05; Figure 19A). This data 
suggest that the protective effects of EMVs may be through activating 
Akt/eNOS signaling pathway.  
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Figure 19. EMVs up-regulate the expression of p-Akt/Akt and p-eNOS/eNOS 
inhibited by Ang II in HbmECs A: Representative western blot bands showing 
p-Akt/Akt and p-eNOS/eNOS expression in HbmECs. B Summarized data for 
p-Akt/Akt and p-eNOS/eNOS expression. Values are the mean ± SEM, n = 4. 
#P< 0.05 vs control; ++P<0.05 vs Ang II. 
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VI. DISCUSSION 
 
The major findings of this study are as follows: 1) Ang 1-7 counteracts the 
deleterious effects of Ang II-induced endothelial dysfunction and apoptosis 
through direct inhibition of Nox2 activity and activation of the PI3K/Akt/eNOS 
signaling pathway. 2) EMVs can also protect endothelial cells against Ang 
II-induced dysfunction and apoptosis by decreasing ROS production and 
activating the Akt/eNOS/NO pathway. 
 
Endothelial dysfunction is a condition in which the endothelium of blood 
vessels does not function normally. It is characterized by reduced vasodilation, 
proinflammatory state and prothrombic properties. Endothelial dysfunction is 
an important early event in the pathogenesis of atherosclerosis, contributing to 
plaque initiation and progression. The severity of endothelial dysfunction has 
been shown to have prognostic value for cardiovascular events. Correction of 
endothelial dysfunction may be associated with reduced cardiovascular risk. 
Mechanisms that participate in the reduced vasodilatory responses in 
endothelial dysfunction include reduced NO, increased oxidative stress. 
Apoptosis (early programmed cell death) of ECs is associated phenomenon. It 
has been documented that upregulation of vasoactive peptides such as Ang II 
induces endothelial dysfunction in vivo and in vitro. In addition, studies 
indicated that ACE inhibitors and AT-1 receptor blockers have protective  
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effects on ECs. Ang 1-7 is a vasodilator peptide counteracting many  
deleterious effects of Ang II induced. However, the detailed mechanism is not 
clear.  
 
In this study, we demonstrated that the ability of HbmEC tube formation is 
impaired by Ang II. We also found that Ang II decreases the expression levels 
of p-Akt and p-eNOS, and NO production in HbmECs; however, increases 
Nox2 expression and ROS production in the HbmECs. These findings are 
supported by previous evidence demonstrating that the RAS plays a key role 
in modulating EC function through regulating NO and ROS production [16;22]. 
Recently, it has been suggested that Ang II inhibits Akt-induced eNOS 
activation and subsequent NO release in ECs [69] and that Ang II infusion 
decreases NO production in aorta by causing eNOS uncoupling. 
One of the major and interesting findings of the present study is that 
pretreatment with Ang 1-7 enhances HbmEC tube formation ability decreased 
by Ang II. Those effects of Ang 1-7 can be partially abolished by Mas receptor 
antagonist (A779), suggesting that Ang 1-7 counteract the effect of Ang II via 
Mas receptor dependent pathway.  
 
Previous studies have suggested that Ang1–7 could against Ang II-induced 
apoptosis in other types of ECs. Consistent with previous reports, we found 
that Ang II enhances apoptosis and that Ang 1-7 inhibits Ang II-induced 
apoptosis in HbmECs. Alone, Ang1–7 had no effect on HbmEC apoptosis. The 
AT-1 receptor antagonist losartan almost completely abolished the Ang II 
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induced apoptosis. The Mas receptor antagonist A-779 almost completely 
abolished the suppression by Ang1–7 of Ang II-induced apoptosis, suggesting 
that Ang1–7 specifically ameliorates Ang II-induced apoptosis. The data 
suggest that Ang 1–7 may be used to improve Ang II-induced apoptosis and 
consequently improve Ang II-associated diseases. Interestingly, preincubation 
of PI3K inhibitor LY294002 partially abolished the suppression by Ang 1-7 on 
Ang II-induced apoptosis, suggesting the PI3K activation is also involved in the 
antiapoptotic effects of Ang 1-7 induced. In contrast with its anti-apoptotic 
effects, Ang1–7 has also been reported to induce apoptosis in circulating 
fibrocytes and human lung cancer cells . Thus, the anti-apoptotic effect of Ang 
1–7 is dependent on the cell type. We are not certain that the anti-apoptotic 
effects of Ang 1-7 will be applicable to all types of ECs.  
 
Oxidative stress is one of the important factors that increase endothelial 
permeability. ROS play an important role in EC dysfunction and a family of 
NADPH oxidases (Noxs) is the major source of ROS involved in redox 
signaling. Previous studies have also proven that Ang II increase ROS 
production through activates Nox pathway in various cell types, including 
vascular smooth muscle, fibroblasts, ECs and cardiomyocytes. However, 
vascular Noxs are expressed in a cell-specific manner, with ECs expressing 
mainly Nox2 and Nox4; vascular smooth muscle cells, Nox1, Nox2, and Nox4; 
and fibroblasts, Nox2 and Nox4. Our study demonstrated that Ang II was able 
to induce overproduction of ROS and activation of Nox2 activity in cultured 
HbmECs. Whereas, preincubation of Ang 1-7 can block Ang II-induced ROS 
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production, through down-regulation of Nox2 activity. The effects of Ang II and 
Ang 1-7 induced were abolished by their selective receptor antagonist losartan 
and A779, respectively. Thus, Ang 1-7 attenuates Ang II-induced oxidative 
stress through Mas receptor.  
 
Ang II induced overproduction of ROS seem also to be involved in the 
mediation of endothelial injury leading to programmed cell death or apoptosis. 
Recently, it has been suggested that Ang II inhibits Akt-induced eNOS 
activation and NO release in ECs. Of note, in addition to activation of NADPH 
oxidase and inhibition of Akt/eNOS signaling cascades, other cellular signaling 
also involved in Ang II-induced deleterious effects, such as protein kinase C 
activation, calcium (Ca2+) loading and phosphorylation of mitogen-activated 
protein kinase (MAPK). In this study, we evaluated the possible mechanisms 
by which Ang 1-7 may positively interfere in the RAS signaling in HbmECs. 
Our data demonstrates that the exposure of HbmECs to Ang 1-7 was directly 
able to activate the signaling pathway producing NO, a molecule that 
possesses some vasoprotective effects. Akt and eNOS are two crucial 
enzymes in this signaling pathway. Their activation is related to a serine 
phosphorylation, which is significantly inhibited by Ang II through the AT1R 
stimulation. On the contrary, Ang 1-7 counteracts the inhibitory effects of Ang II 
on them. The use of receptor antagonists indicates that the effects of Ang 1–7 
are largely mediated by Mas receptor. Moreover, the PI3K activation is an 
important step for the Akt recruitment that it is necessary to activate the eNOS 
signaling and subsequently NO production. Our study confirms that the 
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PI3K/Akt axis is also crucial in the effects mediated by Ang1–7. In fact, Ang1–7 
is able to promote the Akt and eNOS serine phosphorylation that is inhibited by 
the LY294002, a selective PI3K inhibitor. Our data suggest that the exposure 
of HbmECs to Ang1–7 is directly able to activate the signaling pathway 
producing NO, a key biological molecule involved in the preservation of 
endothelial function and vascular integrity. The biological relevance of this 
finding is supported by the demonstration that Ang1–7 is able to induce an 
endothelium-dependent vasodilation in mice arteries, similarly to that exerted 
by muscarinic receptor stimulation. This data add new information to previous 
reports showing the protective role of Ang 1-7 in cells. Our results highlight the 
importance of the Ang 1-7/Mas axis as a potential regulator of endothelial 
function. 
 
The most exciting finding of this study is that we demonstrate that EMVs can 
be uptaken by target HbmECs and the incorporation of EMV inhibits Ang 
II-induced dysfunction and apoptosis in HbmECs. Activation of Akt/eNOS 
activity is possibly involved in EMV-mediated protection against apoptosis. We 
use flow cytometric analysis to assess the surface markers of EMVs, we found 
EMVs were carry their parent proteins and express the markers as their parent 
cells (CD144 for endothelial cells). We examined the size and morphology of 
EMV using the TEM, we found the EMVs are membrane-bound vesicles and  
had a spheroid morphology. The size is around 100 nm or bigger, that's 
consistent with other's reports. The NTA reveal that EMVs have a 
heterogenous size population. Since this is only one time experiment, we did 
60 
 
 
not adopt this EMV concentration for our later experiments but use the protein 
concentration of 10µg/ml to our further experiments. In this study, we also 
demonstrate that EMVs can be uptaken by target cell in a time-dependent 
manner and we apply for the time point 24 hours as our further experiment 
according to others reports. 
 
EMVs have been shown to act as a paracrine mediator as they can merge with 
target cells for exerting their functions. Several studies have demonstrated that 
EPC-MVs can protect ECs from cell dysfunction and apoptosis by Ang II and 
other risk factors. But not much data is available for the role of EMVs in 
regulating endothelial function. In this study, we generated MVs from HbmECs 
which starvation and examined its effects of on HbmEC treated with Ang II. We 
found the tube formation ability and NO production that were compromised by 
Ang II were increased after EMV treatment, accompany with decreased ROS 
production. More interestingly, the expression of Akt and eNOS were 
up-regulated in HbmECs treated with EMVs when compared to Ang II 
treatment. This data indicates that EMVs could protect HbmEC dysfunction 
through activating NO pathway and decreasing ROS production.  
We demonstrated that inhibition of Akt/eNOS signaling pathway was involved 
in endothelial dysfunction induced by Ang II. EMVs activated the Ang II- 
induced Akt/eNOS inhibition after Ang II treatment. These findings, in 
accordance with other data, MVs regulate Akt/eNOS activity and thereby 
mediate protective effects. Nevertheless, the detailed mechanisms of their 
roles need further investigation. 
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VII. CONCLUSION 
 
Our data demonstrate that Ang 1-7 could protect cerebral endothelial cell 
dysfunction and apoptosis induced by Ang II, this functional role might rely on 
Nox/ROS and PI3K/Akt/eNOS pathway. Also, our data suggests that EMVs 
could protect Ang II-induced cerebral endothelial dysfunction, their functional 
role might rely on in the control of ROS production and Akt/eNOS/NO pathway 
in the target cells. This finding indicates that both Ang 1-7 and EMVs could be 
used to treat Ang II-induced endothelial dysfunction. 
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